At a meeting with Goldman Sachs analysts, CEO Ian Read (pictured) indicated that he was willing to consider further divestment of non-core assets. According to analyst Jami Rubin, “a potential full-scale breakup” of Pfizer is on the cards.
At a meeting with Goldman Sachs analysts, CEO Ian Read (pictured) indicated that he was willing to consider further divestment of non-core assets. According to analyst Jami Rubin, “a potential full-scale breakup” of Pfizer is on the cards.
No comments:
Post a Comment